ARS Pharmaceuticals files for approval of neffy in China, Japan and Australia

ARS Pharmaceuticals (SPRY) announced that its licensing partners in China, Japan and Australia have filed for approval of neffy epinephrine nasal spray 2 mg in their respective countries. neffy 2 mg was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to 30 kg, the company noted. ARS Pharma retains all U.S. rights for neffy and has existing licensing partnerships in China, Japan, Australia and New Zealand with Pediatrix Therapeutics, Alfresa Pharma, and CSL Seqirus, respectively. ARS Pharma also has an exclusive agreement with ALK-Abello to commercialize neffy in Europe, marketed as EURneffy in the European Union and obtained EU approval in August, Canada and other geographies outside the United States, the company noted.